PARIS--(BUSINESS WIRE)--CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, providing an alternative for people suffering from end-stage heart failure, announces the first implantation of its artificial heart, as part of its feasibility study and in accordance with the approvals granted by the ANSM (Agence nationale de sécurité du médicament et des produits de santé, the French health authority) and the Comité de Protection des Personnes (ethics committee).
The procedure was performed on December 18, 2013 by the Georges Pompidou European Hospital team in Paris (France) - a world first.
This first implant went smoothly, with the prosthesis automatically providing normal blood flow at a physiological rate. The patient is currently being monitored in intensive care. He is awake and able to talk to his family.
“We are delighted with this first implant, although it is obviously far too early to draw conclusions given that this is the first such implant and surgery has only just been performed”, says Marcello Conviti, Chief Executive Officer of CARMAT.
About CARMAT: the world’s most advanced total artificial heart project.
The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT’s aim is to be able to provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.
For more information: www.carmatsa.com
